|
|
Gene Symbol |
HSD17B1 |
|
Aliases |
17-beta-HSD, 20-alpha-HSD, E2DH, EDH17B2, EDHB17, HSD17, SDR28C1 |
|
Entrez Gene ID |
|
|
Gene Name |
Hydroxysteroid 17-beta dehydrogenase 1 |
|
Chromosomal Location |
17q21.2 |
|
HGNC ID |
|
|
Summary |
This gene encodes a member of the 17beta-hydroxysteroid dehydrogenase family of short-chain dehydrogenases/reductases. It has a dual function in estrogen activation and androgen inactivation and plays a major role in establishing the estrogen E2 concentration gradient between serum and peripheral tissues. The encoded protein catalyzes the last step in estrogen activation, using NADPH to convert estrogens E1 and E2 and androgens like 4-androstenedione, to testosterone. It has an N-terminal short-chain dehydrogenase domain with a cofactor binding site, and a narrow, hydrophobic C-terminal domain with a steroid substrate binding site. This gene is expressed primarily in the placenta and ovarian granulosa cells, and to a lesser extent, in the endometrium, adipose tissue, and prostate. Polymorphisms in this gene have been linked to breast and prostate cancer. A pseudogene of this gene has been identified. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2016]
|
|
e!Ensembl
|
Protein Information |
|
Protein Name |
Estradiol 17-beta-dehydrogenase 1, 17-beta-HSD 1, 17-beta-hydroxysteroid dehydrogenase type 1, 20 alpha-hydroxysteroid dehydrogenase, placental 17-beta-hydroxysteroid dehydrogenase, short chain dehydrogenase/reductase family 28C member 1, short chain dehydrogenase/reductase family 28CE, member 1 |
|
Function |
Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity. Uses preferentially NADH |
|
|
UniProt |
|
|
PDB |
1A27, 1BHS, 1DHT, 1EQU, 1FDS, 1FDT, 1FDU, 1FDV, 1FDW, 1I5R, 1IOL, 1JTV, 1QYV, 1QYW, 1QYX, 3DEY, 3DHE, 3HB4, 3HB5, 3KLM, 3KLP, 3KM0, 6CGC, 6CGE, 6DTP, 6MNC, 6MNE |
|
Pfam |
Pfam Accession |
Pfam ID |
PF00106 |
adh_short |
|
|
|
|
Interactions |
| |
STRING |
MINT |
IntAct |
ENSP00000466799 |
|
P14061 |
|
| |
View interactions
|
|
| |
Associated Diseases
Disease group | Disease Name | References |
Endocrine System Diseases |
PCOS |
|
Immune System Diseases |
Autoimmune Diabetes |
|
Neoplasms |
Breast Cancer |
|
Lung Cancer |
|
Liver Cancer |
|
Leiomyosarcoma |
|
Endometrial Cancer |
|
Colorectal Cancer |
|
Gastric Cancer |
|
Leukemia |
|
Cervical Cancer |
|
Prostate cancer |
|
Skin Cancer |
|
Nervous System Diseases |
Amyloid Polyneuropathy |
|
Reproductive disorders |
Endometriosis |
|
Infertility |
|
Pregnancy associated hypertension |
|
|
References |
|
|
|
PubMed ID |
Associated gene/s |
Associated condition |
Genetic Mutation |
Diagnostic Criteria |
Association with PCOS |
Ethnicity |
Conclusion |
|
|
PCOS, Lipid metabolism, Steroidogenesis and follicular growth |
|
|
Direct
|
39 PCOS subjects and 30 PCOS controls |
The present study discloses decrease in insulin signaling proteins related to metabolism, lipogenic genes and steroidogenesis in PCOS-IR group as against decrease only in steroidogenesis in PCOS-NIR group. These differential signaling molecules ultimately might be involved in the prevalence of hyperinsulinemia and hyperandrogenemia in PCOS-IR group and intrinsic ovarian defects in PCOSNIR group leading to follicular arrest, poor oocyte growth as well as quality observed in different PCOS phenotypes. The study would aid in designing candidate molecules for targeted therapy towards the two different types of PCOS thus decreasing probability of reproductive failures. |
|
|
|
|